There are currently 9 active clinical trials seeking participants for Idiopathic Pulmonary Fibrosis research studies. The states with the highest number of trials for Idiopathic Pulmonary Fibrosis participants are .
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Recruiting
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +371 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Recruiting
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +179 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Recruiting
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Quilmes, Buenos Aires +79 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/17/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +502 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has com... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/11/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +113 locations
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/09/2025
Locations: Royal Prince Alfred Hospital, Camperdown, New South Wales +72 locations
Conditions: Idiopathic Pulmonary Fibrosis
High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib
Recruiting
The purpose is to determine if patients with idiopathic pulmonary fibrosis (IPF) taking nintedanib will have improved exercise endurance, breathlessness and quality of life if breathing 60% oxygen compared to standard of care during an 8 week exercise training program.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
01/15/2025
Locations: University of Calgary, Calgary, Alberta +7 locations
Conditions: Idiopathic Pulmonary Fibrosis
Skeletal Muscle Function in Interstitial Lung Disease
Recruiting
Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
01/14/2025
Locations: St. Paul's Hospital, Vancouver, British Columbia
Conditions: Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Scleroderma, Nonspecific Interstitial Pneumonia
Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).
Recruiting
Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease marked by reduced exercise capacity and activity-related breathlessness (commonly termed dyspnea). Our previous work has shown that dyspnea during exercise is associated with an increased drive to breathe (inspiratory neural drive; IND). However, little work has been done to understand the mechanisms of exertional dyspnea in patients with mild IPF. The objectives of this study are to compare the acute effects of inhaled nitric oxi... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/01/2024
Locations: Respiratory Investigation Unit, Kingston General Hospital, Kingston, Ontario
Conditions: Idiopathic Pulmonary Fibrosis